Thymosin ␣ 1 (T␣1) is an immunomodulatory polypeptide that enhances effector T-cell responses. In this large randomized study, we evaluated the efficacy and safety of combining T␣1 with dacarbazine (DTIC) and interferon alfa (IFN-␣) in patients with metastatic melanoma.
INTRODUCTION
Melanoma is the most common nonhematopoietic cancer in young adults (15 to 34 years of age), and the incidence of the disease is increasing alarmingly worldwide.
1 Prognosis for patients with metastatic melanoma is very poor. In a recent meta-analysis of 42 phase II trials, median survival was only 6.2 months, with a mean 1-year survival rate of 25.5% regardless of treatment regimen. Dacarbazine (DTIC) is considered the benchmark treatment for advanced melanoma, despite response rates (RR) of less than 10% in contemporary trials. [3] [4] [5] [6] [7] [8] Given the known immunogenicity of melanoma, 9-11 many studies have evaluated the combination of chemotherapy with immunotherapy, particularly regimens containing interferon alfa (IFN-␣) and interleukin-2 (IL-2). 12 Although some of these studies have reported durable tumor responses 13,14 or increased progression-free survival (PFS), 15 no regimen to date has improved overall survival (OS) versus standard care. Furthermore, chemoimmunotherapy is generally associated with considerable toxicity compared with chemotherapy alone.
13,15,16 Therefore, there is strong rationale for assessing novel and possibly less toxic immunotherapeutic approaches in patients with metastatic melanoma.
Thymosin ␣ 1 (T␣1; Zadaxin; SciClone Pharmaceuticals International, San Mateo, CA) is an immunomodulatory polypeptide that could potentially improve efficacy of treatment regimens for metastatic melanoma without impacting toxicity. T␣1 is produced endogenously by the thymus
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gland 17 and augments T-cell-mediated immune responses by several mechanisms, including stimulation of T-cell differentiation and/or maturation, 18 activation of natural killer 19 and dendritic cells, 20 and stimulation of proinflammatory cytokine release. 21, 22 Pilot studies in patients with advanced melanoma suggest that T␣1 may improve the efficacy of DTIC-based regimens. 23, 24 Importantly, T␣1 has demonstrated a very favorable toxicity profile in more than 2,000 individuals treated to date, including patients with hepatocellular carcinoma, 25 non-small-cell lung cancer, 26 ,27 melanoma, 23, 24 and hepatitis B and C. 28 Therefore, there is strong rationale for combining T␣1 with regimens in development for the treatment of advanced melanoma (Appendix, online only).
Here we report results from a large, multicenter, open randomized study to investigate the efficacy of T␣1 administered in combination with DTIC or with DTIC plus IFN-␣ versus DTIC plus IFN-␣ in patients with metastatic melanoma.
PATIENTS AND METHODS

Patients
Patients were 18 to 75 years old, with histologically or cytologically confirmed stage IV melanoma with unresectable metastases and one or more measurable lesions. All patients had Eastern Cooperative Oncology Group performance status 0 or 1, serum creatinine levels less than 1.5 mg/dL, absolute neutrophil count Ն 1.5 ϫ 10 9 /L, platelet count Ն 100 ϫ 10 9 /L, and life expectancy Ն 12 weeks. Patients had measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Exclusion criteria included previous chemotherapy or treatment with T␣1, CNS metastasis, and ocular or mucosal melanoma.
Study Design
The study was conducted at 64 centers in eight European countries between August 2002 and January 2006. Patients were stratified according to American Joint Committee on Cancer (AJCC) staging criteria. 29 According to the original study design, patients were randomly assigned to four treatment arms: DTIC plus IFN-␣ and 1.6 mg of T␣1 (DIT1.6 group; accrual target: 65 patients), DTIC plus IFN-␣ and 3.2 mg of T␣1 (DIT3.2 group; 65 patients), DTIC and 3.2 mg of T␣1 (DT3.2 group; 95 patients), and DTIC and IFN-␣ (DI group; 95 patients). Eligible patients were randomly assigned 1:1:2:2 to each group. Randomization was blinded and centralized at MDS Pharma Services Centro Direzionale Milanofiori, Assago, Italy. The randomization list was produced by the Internal Quality Control Unit of Biostatistics and Data Management, Sigma-Tau. Preliminary analysis of the primary end point was undertaken by the study steering committee once accrual was 45% complete to monitor efficacy results. This analysis revealed a potential dose-response pattern in the DIT1.6 and DIT3.2 groups and a lower than expected overall RR (ORR) in the DI group. Consequently, the study sponsor and steering committee requested an extension to the original protocol to incorporate a DTIC plus IFN-␣ and 6.4 mg of T␣1 group (DIT6.4 group; accrual target: 95 patients) and to increase the sample size in the DIT1.6 and DIT3.2 groups (modified accrual target: 95 patients per group). The extension was requested in consideration of the urgent need for new therapies for melanoma, the favorable safety profile of T␣1 to date, and the exploratory nature of the study. Nevertheless, the study extension compromised the power of intergroup comparisons planned in the original protocol, and the five treatment arms had to be analyzed independently. For the extended study, patients were randomly assigned 1:1:2 to the DIT1.6, DIT3.2, and DIT6.4 groups, respectively.
Treatment was administered for a maximum of six 28-day cycles, unless the investigator specified otherwise. DTIC (800 mg/m 2 ; intravenously [IV]) was given on day 1; T␣1 (subcutaneously [SC] ) was given on the morning of days 8 to 11 and 15 to 18; and IFN-␣ (3 MU; SC) was given on the evening of days 11 and 18. Treatment was continued until disease progression (increase Ն 20% in the sum of the longest diameters of the target lesions and/or new lesions), development of any serious adverse event (AE), or withdrawal of consent. Tumor response was observed for up to 12 months after the initiation of treatment; patient survival was observed for up to 24 months.
The study was carried out in compliance with the Declaration of Helsinki, Good Clinical Practice Guidelines, and all applicable local regulatory requirements. The study protocol and amendments were approved by a local independent ethics committee. Signed, informed consent was obtained from patients before initiation of any specific procedures.
Study Outcomes
The primary end point was ORR (complete responses [CR] plus partial responses [PR]), which was analyzed independently in each treatment arm. Up to 10 measurable lesions were assessed at baseline, after cycles 2, 4 and 6, and at 9-and 12-month follow-up visits, according to RECIST guidelines. Independent, blinded evaluation of tumor images was performed by Fondazione Biomedica Europea.
Secondary end points included duration of response, OS, and PFS. Duration of response was defined as time elapsed between first documented response and start of new antitumor therapy, disease progression, or death. OS was defined as time elapsed from random assignment to death from any cause. PFS was defined as time elapsed from random assignment to start of new antitumor therapy, disease progression, or death. Plasma lactate dehydrogenase (LDH) levels were assessed centrally; elevated levels were confirmed independently. Safety and tolerability assessment included observed AEs, clinical laboratory tests, physical examinations, and vital sign assessments using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. These were carried out at baseline and between days 19 to 28 of each cycle; AEs were recorded for up to 3 months after the last administered dose. AEs were classed as treatment-related or unrelated according to investigator judgement based on the combination of therapies received by the patient.
Statistical Analysis
Determination of sample size. Determination of sample size was based on the primary end point (ORR). Given the exploratory nature of this large randomized study, sample size computation was not adjusted for the interim analysis performed on 45% of the originally planned sample. Based on previous studies, 3,5,8 the ORR was expected to be Յ 5% for standard therapy (P 0 ) given the patient distribution across AJCC staging criteria. An ORR of Ն 15% would be considered significantly better than standard therapy (P 1 ). To test the null hypothesis (P 0 Յ 5%) versus the alternative hypothesis (P 1 Ն 15%) with a power of 95%, 93 patients would be required in each of the treatment arms assuming ␣ ϭ 0.05. As the DIT6.4 group was added subsequently to the original treatment allocation, sample size was calculated differently for this group and was based on a two-stage Simon's optimal design. For the first stage, it was estimated that 56 patients would be required to test the null hypothesis with 95% power. If the null hypothesis was not supported at stage 1, the sample size would be extended to 95 patients.
Efficacy analysis. All randomized patients (intent-to-treat [ITT] population) were included in the primary efficacy analysis. Efficacy end points were also assessed in the per-protocol (PP) population, defined as patients who fulfilled all inclusion criteria, did not fulfill any exclusion criteria or use prohibited medications, and were fully compliant with study treatment. A twosided significance level of .05 was used. In each treatment arm, the null hypothesis (P 0 Յ .05) was rejected in favor of the alternative hypothesis (P 1 Ն .15) if nine or more tumor responses were observed at study end. Secondary analyses of the primary end point included assessment of overall activity in the triple therapy groups combined (DIT1.6 ϩ DIT3.2 ϩ DIT6.4) versus both the DI and DT3.2 groups. Intergroup comparisons were undertaken using exact logistic regression stratified by AJCC stage. Two-sided CIs were computed for each comparison.
The secondary end points were examined using descriptive analyses; OS and PFS were estimated by constructing Kaplan-Meier curves. For exploratory analyses, treatment groups were compared using the log-rank test stratified by stage of disease. Hazard ratios (HRs) and related 95% CIs were calculated for each comparison using a Cox proportional hazards model. Patients lost to follow-up or not progressed at time of analysis were censored.
Safety analysis.
All patients who had received one or more dose of study treatment were included in the safety and tolerability analysis (safety population). AEs were classified and graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 and included evaluation of clinically significant laboratory test results and vital signs. AEs were classified according to system organ class (SOC) and were compared between treatment groups by 2 test. If a SOC demonstrated a significant difference between arms, the analysis was extended to each AE within that SOC.
RESULTS
Patients
Between August 2002 and January 2006, 571 patients with confirmed metastatic melanoma were assessed for eligibility; 488 patients met the eligibility criteria and were randomly assigned between the five treatment groups (Fig 1) . Patient demographics were similar between study arms (Table 1) .
Efficacy
Tumor response data for each study arm are shown in Table 2 . Ten and 12 confirmed responses were observed in the DIT3.2 and DT3.2 groups, thereby rejecting the null hypothesis (P 0 Յ .05) in these two arms. ORR was numerically higher in patients treated with any T␣1-containing regimen versus patients in the DI group for each of the three AJCC strata (M1a, 15.7% v 0.0%; M1b, 11.8% v 8.0%; M1c, 6.5% v 3.3%). In the ITT population, there was no significant difference in ORR between any of the treatment groups. However, in the PP population, ORR was significantly higher in the DT3.2 group compared with the DI group (odds ratio ϭ 4.1; 95% CI, 1.04 to 23.25; P ϭ .04). There was no significant difference in ORR in patients receiving triple therapy (DIT1.6 ϩ DIT3.2 ϩ DIT6.4) versus the DI group or versus the DT3.2 group in either the ITT or PP populations. Duration of response ranged from 1.9 to 23.2 months in patients given any T␣1-containing regimen compared with 4.4 to 8.4 months in the control group (Table 2) . For the nine patients who achieved a CR after treatment with T␣1, duration of response ranged from 3.7 to 23.2 months. All nine patients were alive after 1 year, and seven patients were alive after 2 years. Clinical benefit rates (CRϩPRϩstable disease) were numerically higher in patients treated with a T␣1-containing regimen (37.1% to 49.5%) versus the control group (32.0%; Table 2 ). The difference between the DT3.2 group and control group was statistically significant (P ϭ .009). Median OS was 6.6 months in the DI group and ranged from 8.6 to 10.3 months in the other groups, with no statistically significant differences between groups (Table 2; Fig 2A) . There was a trend toward improved OS in patients given any T␣1-containing regimen versus the DI group (HR ϭ 0.80; 95% CI, 0.63 to 1.02; P ϭ .08; Fig 2B) . This comparison reached statistical significance in the PP population (HR ϭ 0.74; 95% CI, 0.57 to 0.95; P ϭ .02). Posthoc Cox regression analysis on OS demonstrated that there was no significant interaction between baseline LDH levels and treatment (data not shown). The 12-month survival rate was 34.2% in the DI group and ranged from 37.1% to 45.5% in the other groups (Table 2) .
Median PFS ranged between 1.8 and 2.0 months (Table 2 ; Fig  2C) . Compared with the DI group, PFS was significantly higher in the DT3.2 group (HR ϭ 0.73; 95% CI, 0.54 to 0.99; P ϭ .04; Fig 2C) , with a trend in the total T␣1 group (HR ϭ 0.80; 95% CI, 0.63 to 1.01; P ϭ .06; Fig 2D) . Posthoc Cox regression analysis on PFS demonstrated a significant interaction between baseline LDH and treatment. In patients with normal LDH levels (Յ upper limit of normal), median PFS ranged from 3.4 to 3.7 months in patients treated with T␣1 and was significantly higher in each T␣1-containing regimen versus the DI group (Table 2 ). The 6-month PFS rate was 9.1% in the DI group and ranged from 11.7% to 21.1% in the other groups (Table 2) .
Safety
The mean number of treatment cycles ranged from 3.7 in the DI group to 4.1 to 4.5 in the other groups. A total of 38 patients discontinued treatment owing to AEs (4.2% in the DI group, 10.3% in the DIT1.6 group, 6.2% in the DIT3.2 group, 7.1% in the DIT6.4 group, and 11.2% in the DT3.2 group). Treatment was reduced or interrupted owing to AEs in 17 patients (4.2% in the DI group, 4.1% in the 1.8 to 2.6 1.8 to 2.0 1.8 to 2.6 1.8 to 3.5 1.7 to 2.0 HR for PFS 0.9 0.7 § 0.8 0.7 § 95% CI 0.6 to 1.2 0.5 to 1.0 0.6 to 1.1 0.5 to 1.0 Median PFS, months, in patients with LDH Յ ULN 3.4 ‡ 3.5 ‡ 3.4 ‡ 3.7 ‡ 2.0 95% CI 1.8 to 3.8 1.8 to 4.1 1.8 to 3.8 2.0 to 5.5 1.8 to 3.1 HR for PFS in patients with LDH Յ ULN 0.7 § 0.6 § 0.6 § 0.7 § 95% CI 0.5 to 1.0 0.4 to 0.9 0.4 to 0.8 0.4 to 1.0 6-month PFS, %; Kaplan-Meier estimate 11.7 21.1 13.5 15.9 9.1 95% CI 5.2 to 18.2 12.9 to 29.3 6.5 to 20.5 8.4 to 23.3 3.1 to 15.1
Abbreviations: DIT, dacarbazine (DTIC) plus interferon alfa (IFN-␣) and thymosin ␣ 1 (T␣1); DT, DTIC plus T␣1; DI, DTIC and IFN-␣; CR, complete response; PR, partial response; PD, progressive disease; OR, overall response; OS, overall survival; HR, hazard ratio; ULN, upper limit of normal; PFS, progression-free survival; LDH, lactate dehydrogenase.
DIT1.6 group, 4.1% in the DIT3.2 group, 2.0% in the DIT6.4 group, and 3.1% in the DT3.2 group). The number of patients experiencing treatment-related AEs and serious AEs (SAEs) during the treatment period and followup was similar in each group (Table 3 ). Significant differences (P Ͻ .05) were detected between study arms for three SOCs: gastrointestinal disorders, general disorders and administration site conditions, and nervous system disorders (Table 4) . Of the AEs that showed significant differences in frequency between study arms, only pyrexia was considered serious and was judged unrelated to treatment.
A total of 41 treatment-related SAEs were observed in 36 patients (Table 3) . Of these SAEs, 11 led to death. SAEs classified as probably, or certain to be, related to study drug included two cases of grade 4 neutropenia in the DIT3.2 arm and a case of grade 3 hematemesis in the DT3.2 arm. 
DISCUSSION
This study was designed to assess whether T␣1 could potentiate the efficacy of DTIC (with or without IFN-␣) in the treatment of metastatic melanoma. Ten and 12 confirmed responses were observed in the DIT3.2 and DT3.2 groups, thereby rejecting the null hypothesis of P0 Յ .05 in these two arms. Moreover, several durable responses were observed in patients given T␣1; median duration of response ranged from 1.9 to 23.2 months. Encouragingly, there was a trend toward improved OS in patients given T␣1 versus the DI group. Furthermore, 1-year survival, regarded as a key benchmark for comparing efficacy of novel therapeutic regimens versus historical data, 2 ranged from 37.1% to 45.5% in patients treated with T␣1. By contrast, a meta-analysis of 42 previous phase II trials reported a mean 1-year survival of 25.5% in patients with advanced melanoma.
2 Also, PFS was significantly improved in patients given T␣1 versus the control group, particularly in those with normal baseline LDH levels. Importantly, the frequency and severity of AEs were not affected by the presence of T␣1 in treatment regimens. No conclusions could be made regarding the optimal dose of T␣1 in the current study because of the incorporation of a major extension to the original protocol, and this will assessed in further studies. Overall, however, this trial strongly supports further clinical assessment of DTICϩT␣1 in patients with metastatic melanoma.
To date, attempts to enhance effector T-cell responses in patients with metastatic melanoma, either exogenous cytokines 12,30-32 or specific vaccines, 33 have been largely unsuccessful. A more encouraging immunotherapeutic approach may be the blockade of anticytotoxic T-lymphocyte antigen (CTLA-4). In phase II trials, 1-year survival rates of between 47% and 53% were demonstrated with ipilimumab.
34-36 However, grade 3 to 4 immune-related AEs were experienced in approximately 25% of patients. 37, 38 Furthermore, a phase III trial of tremelimumab was discontinued because survival was not improved versus chemotherapy. 37 Other regimens that have shown promising clinical activity in patients with metastatic melanoma include oblimersen sodium plus DTIC, 3 sorafenib plus DTIC, 38 and elesclomol plus paclitaxel. 39 Although some of these combinations have improved PFS or OS compared with standard care in phase II trials, these findings have yet to be confirmed. In the context of other clinical trials, therefore, the results of the current study are encouraging and provide the basis for further studies combining DTICϩT␣1 in patients with metastatic melanoma. Given that PFS correlated with plasma LDH levels in the current study, and the prognosis of patients with elevated LDH levels (OS of approximately 6 months) is poor, 40 LDH would be an informative stratification factor in future phase III evaluation of DTICϩT␣1.
Although the mechanism underlying the activity of DTICϩT␣1 is not fully understood, it is possible that T␣1 potentiates T-cellmediated immune responses directed against tumor antigens released from cells destroyed by DTIC. It is known that tumor-cell apoptosis induced by cytotoxic agents can increase levels of cross-presentation of tumor antigens by specialist antigen-presenting cells, such as dendritic cells. 41 However, this phenomenon is, in itself, usually not sufficient to induce an immune response in the absence of proinflammatory signals within the tumor microenviroment. 42 In this respect, the capacity of T␣1 to prime immune responses, via pleiotropic mechanisms, may be important. A mechanistic link between DTIC and T␣1 may be related to the fact that T␣1 can activate Toll-like receptor 9 (TLR9) on dendritic cells, 43 as this receptor is particularly important in enhancing antitumor T-cell responses. 44, 45 Furthermore, an immunologic basis for the activity of DTIC and T␣1 is suggested by the patterns of response observed in this study. The high rates of stable disease (26% to 37%) observed in patients treated with T␣1 are characteristic of immunotherapy, where the decline in tumor 
